Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients

Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany
Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )
10 Dec 2015

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival

Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA
Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Dec 2015

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients

Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA
Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Dec 2015

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B ( Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA )
10 Dec 2015

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015

Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers

Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA
Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers ( Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA )
9 Dec 2015

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015

Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015

Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015

Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer

Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA
Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )
9 Dec 2015